From Applications to Experimentation: The Journey Behind the EVOLVE2CARE Open Call

Behind every successful experimentation phase lies a carefully designed selection process.

For EVOLVE2CARE, the Open Call was not simply a call for proposals. It was the foundation of a structured pathway connecting HealthTech innovators with Living Labs across Europe. The Open Call marked the transition from interest to engagement, and from ideas to implementation.

This blog builds on insights from Deliverable D2.2 – “Living Labs, Innovators and Researchers Scouting and Selection Report”, which is publicly available on Zenodo and provides a transparent overview of the scouting, evaluation, and selection process behind the EVOLVE2CARE Open Call.

Designing an Open Call with Purpose

HealthTech innovation thrives when solutions are tested where care actually happens. With this in mind, the EVOLVE2CARE Open Call focused on identifying innovators and Living Labs ready to collaborate in three critical domains of transitional care:

  • Hospital discharge management
  • Remote monitoring and home-based care
  • Ageing and chronic care support

The objective was not only to select promising technologies, but to ensure alignment between innovators’ ambitions and the real-world experimentation capacity of Living Labs.

A Structured and Transparent Process

The scouting and selection process was designed to be clear, fair, and impact-oriented.

Applications were evaluated against predefined criteria that considered:

  • Relevance to transitional care use cases
  • Technical feasibility and maturity
  • Potential for measurable impact
  • Readiness for collaboration within Living Lab environments

Beyond scoring, the process also focused on matchmaking, ensuring that selected innovators were paired with Living Labs capable of supporting meaningful experimentation.

This structured approach ensures that the experimentation phase is grounded in strategic alignment rather than opportunistic selection.

From Selection to Real-World Validation

With the Open Call phase completed, selected mini-projects have now entered Living Lab environments for real-world experimentation.

This marks a critical shift. The focus moves:

  • From proposal quality to implementation performance
  • From theoretical value to practical usability
  • From innovation potential to measurable impact

Within Living Labs, solutions are tested in real healthcare contexts, involving professionals, patients, and ecosystem actors. This enables innovators to refine their tools, identify integration challenges early, and generate evidence that goes beyond technical feasibility.

Building Evidence for Sustainable Uptake

The Open Call was the first step in a broader journey toward sustainability and scalability.

By documenting the scouting and evaluation methodology, EVOLVE2CARE reinforces its commitment to transparency and replicability. The structured selection process lays the groundwork for credible experimentation outcomes, stronger positioning of project results, and future ecosystem adoption.

Readers interested in understanding the full methodology behind the Open Call scouting and selection process can explore Deliverable D2.2 – “Living Labs, Innovators and Researchers Scouting and Selection Report”, available publicly on Zenodo.

From applications to experimentation, EVOLVE2CARE continues to build a pathway where innovation is not only selected, but validated, strengthened, and positioned for real-world healthcare transformation.

EVOLVE2CARE in Athens: Aligning for Impact and Sustainability

On 17–18 February 2026, the EVOLVE2CARE consortium met in Athens, Greece, for its 4th Plenary Meeting. Held in parallel with Athens Digital Health Week 2026 (ADHW2026) at the Royal Olympic Hotel, the gathering offered more than just coordination updates, it created a moment to reflect, realign, and strengthen the project’s next phase within Europe’s rapidly evolving digital health landscape.

Across two intensive days, partners focused on consolidating the Open Call results, reinforcing the EVOLVE2CARE experimentation framework, advancing the positioning of AccelUP, and scaling outreach and sustainability efforts.

Day 1: From Open Call Results to Real-World Experimentation

The first day was dedicated to a pivotal transition point for the project: moving from Open Call completion to structured implementation in Living Lab environments.

Reflecting on the Open Call Impact

With the Open Calls now officially finalised, the consortium reviewed:

  • Key statistics and insights from the application and selection process
  • Improvements introduced through Deliverable D2.2
  • The shift from recruitment to real-world pilot implementation

Beyond numbers, the discussion focused on impact. How can the lessons learned from the Open Call strengthen communication materials and support the long-term positioning of project outcomes?

The emphasis is now clear: experimentation must generate measurable, documented value within Living Labs.

Strengthening the EVOLVE2CARE Experimentation Framework

Day 1 also included final roadmap presentations for three central deliverables shaping the project’s experimentation model:

  • D1.4 – Roadmap on navigating complexities enabling innovative technologies in transitional care
  • D1.5 – Stakeholder Needs Analysis and KPI Framework
  • D1.6 – EVOLVE2CARE Action Plan

Concrete decisions were taken to reinforce structure and comparability across pilots:

  • Each mini-project will submit a structured “initial context” (solution, target users, key assumptions) before pilots begin, enabling meaningful before/after analysis.
  • A Regulatory & Ethics Log will allow Living Labs to systematically record compliance and data-related issues during implementation.
  • The KPI framework will be disseminated beyond the consortium, engaging relevant European health clusters and sister projects.

Day 2: Connecting Ecosystem Dialogue with Strategic Planning

The second day blended external engagement at ADHW2026 with focused internal alignment on evaluation, outreach, and long-term sustainability.

Engaging the Digital Health Ecosystem at ADHW2026

On the morning of 18 February, EVOLVE2CARE hosted the workshop:

“Engaging the Value of Living Labs to Innovate Healthcare”

Chaired by Despoina Petsani (AUTH), the session brought together innovators, clinicians, researchers, and ecosystem actors to tackle a pressing HealthTech question:

How can promising digital solutions successfully transition from pilot testing to routine clinical practice?

The discussion went beyond technology development and addressed the structural realities of healthcare innovation, including regulatory complexity, GDPR compliance, interoperability limitations, integration into clinical workflows, and fragmented stakeholder collaboration.

Across contributions, Living Labs emerged as structured experimentation environments capable of reducing deployment risks while generating real-world validation.

🔗 Read the full workshop recap here.

Aligning the Next Phase of the Project

Returning to the plenary discussions, partners focused on shaping the next phase of EVOLVE2CARE.

The agenda centred on five strategic priorities:

  • Structuring the evaluation framework for mini-project experimentation
  • Aligning questionnaires and feedback tools for innovators and Living Labs
  • Strengthening AccelUP’s positioning beyond the Open Call phase
  • Expanding participation in European Commission and EIT-related events
  • Planning sustainability and exploitation activities for all project results

Key Highlights from the Discussions

  • Evaluation tools were aligned to ensure structured before/after feedback capturing both technical and market-oriented value.
  • Pricing perception and value-creation questions were integrated into experimentation surveys.
  • Complementary assessment mechanisms were coordinated to ensure systematic data collection.
  • The exploitation approach was further defined, combining questionnaire-based validation with market and competitor analysis.
  • Dissemination efforts will intensify in the “Global Outreach & Sustainability” phase, with stronger participation in European-level events, broader press outreach, and enhanced digital engagement.
  • Strategic planning began for participation in Open Living Lab Days and policy-oriented events to showcase the project’s KPI framework and experimentation insights.

Key Decisions Moving Forward

  • Mini-project evaluation will follow a structured, comparable methodology capturing both experimentation outcomes and market insights.
  • Two internal exploitation workshops will be organized. One dedicated to AccelUP positioning, and another focusing on the remaining project results.
  • Outreach efforts will prioritise European Commission–related events and EIT KIC engagement.
  • Communication efforts will intensify, with coordinated partner promotion and increased focus on subscriber growth and stakeholder engagement.

A Strategic Transition Point

The 4th Plenary Meeting marked a clear evolution for EVOLVE2CARE:

  • From Open Call recruitment to structured pilot implementation
  • From framework design to measurable evidence generation
  • From awareness-building to strategic European outreach
  • From experimentation to sustainability planning

With mini-projects underway, evaluation tools aligned, and exploitation strategy defined, EVOLVE2CARE moves forward with a clearer pathway toward scalable, validated, and ecosystem-integrated HealthTech innovation!

Bridging the Digital Health Innovation Gap – ADHW26 Workshop Recap

Organised by the EVOLVE2CARE project in the context of Athens Digital Health Week 2026, the workshop “Engaging the Value of Living Labs to Innovate Healthcare” took place on 18 February and was chaired by Despoina Petsani, Project Mission Coordinator (AUTH). The session convened innovators, researchers, and ecosystem actors to examine a pressing question in HealthTech: how can promising digital solutions successfully transition from pilot testing to routine clinical practice?

Rather than focusing solely on the generation of new technologies, the discussion addressed the structural and operational barriers that prevent digital health innovations from scaling within real healthcare environments. Speakers highlighted a persistent misalignment between technological development and clinical realities. Digital tools frequently struggle to integrate into established workflows, while regulatory complexity, GDPR compliance, interoperability limitations, and fragmented stakeholder collaboration continue to slow adoption . This creates tension between rapid technological advancement and the healthcare sector’s demand for rigorous validation and governance, often resulting in solutions that are technically robust but operationally stalled.

Spyridoula Trakaki emphasised that startups commonly face systemic barriers to market entry and underscored the importance of open innovation ecosystems in overcoming fragmentation and accelerating uptake. Complementing this perspective, Konstantina Kostopoulou, Chief Product Owner of the Healthentia App, shared practical insights into integration pain points during experimentation, particularly around stakeholder engagement and the initial reactions of clinicians and third parties to new digital tools . Her intervention reinforced the idea that adoption depends not only on technological robustness but also on early trust-building and alignment with end-user expectations.

From a service design standpoint, Thanos Loules and Ilias Rafail of IASIS AMKE explored the challenges of developing inclusive services while maintaining active citizen engagement throughout the experimentation process . They stressed that meaningful co-creation requires sustained involvement rather than superficial consultation. Dr. Angelina Kouroubali further addressed the delicate balance between thorough research and the urgency to bring solutions to market, suggesting that structured experimentation frameworks can reconcile scientific rigor with innovation speed .

Across contributions, Living Labs emerged as a strategic integration mechanism. By enabling structured testing within authentic care settings, they reduce deployment risks, strengthen collaboration among stakeholders, and generate the field-based validation required for broader adoption . Rather than positioning digital tools as external add-ons, Living Labs facilitate their evolution into embedded components of care delivery systems.

The workshop ultimately underscored that sustainable healthcare transformation depends on aligning fast-moving innovation cycles with the operational and regulatory realities of the care sector. Through open ecosystems and Living Lab methodologies, stakeholders can bridge this divide—ensuring that digital health innovations are interoperable, credible, and capable of delivering measurable value in real-world clinical settings .

EVOLVE2CARE Workshop at Athens Digital Health Week 2026

EVOLVE2CARE will participate in Athens Digital Health Week 2026 (ADHW2026) with a dedicated workshop titled:

“Engaging the Value of Living Labs to Innovate Healthcare”

📍 Royal Olympic Hotel, Athens
📅 Wednesday, 18 February 2026
🕙 10:00–11:30 | Kallirhoe Hall

About Athens Digital Health Week 2026

Taking place from 16–20 February 2026, ADHW2026 brings together leading experts, innovators, policymakers, and decision-makers to address critical challenges and showcase breakthrough advancements shaping the future of digital health across Europe and beyond.

Co-organised by IDIKA S.A., the National eHealth Authority (NeHA) of Cyprus, and HL7 Hellas, the event serves as a high-profile networking hub where European projects, governance bodies, and digital health stakeholders connect to accelerate healthcare transformation across Europe.

Workshop Overview

Digital health innovation often encounters significant barriers, including regulatory complexity, interoperability limitations, misalignment with real clinical and user needs, financial constraints, and fragmented stakeholder collaboration.

This EVOLVE2CARE workshop will explore how Living Labs and open innovation ecosystems can help address these challenges by:

  • Strengthening stakeholder engagement
  • Supporting user-centred design
  • Facilitating real-world experimentation
  • Accelerating the translation of innovation into clinical practice

The session will combine theoretical reflections with practical insights drawn from real-world experiences of innovators, clinicians, and ecosystem actors.

Panel Discussion

The workshop will feature short expert interventions from key stakeholders across the digital health ecosystem:

  • Spyridoula Trakaki, Co-Founder of Kakushin, will discuss the main challenges startups face in digital health and reflect on how open innovation ecosystems can create added value for emerging HealthTech ventures.
  • Konstantina Kostopoulou, Chief Product Owner of Healthentia App, will share practical insights on stakeholder integration challenges during experimentation and how clinicians and third parties initially responded to innovation adoption.
  • Thanos Loules & Ilias Rafail (IASIS AMKE) will explore service design challenges in health innovation and discuss how citizens can be meaningfully engaged throughout the experimentation process.
  • Dr. Angelina Kouroubali, Digital Health Expert, will address stakeholder engagement pain points and examine how innovators can balance rigorous research and validation with the urgency of bringing solutions to market.
  • Prof. Dr. Vassilis Vasilikos, Cardiologist, will provide the clinician’s perspective on innovation adoption, highlighting common barriers in clinical practice, nparticularly in cardiology, and attitudes toward integrating digital solutions into healthcare settings.

The session will conclude with an open discussion on how Living Labs can strengthen collaboration, enhance experimentation processes, and accelerate the translation of digital health innovation into sustainable real-world impact.

The workshop will be facilitated by the EVOLVE2CARE coordinator team from Aristotle University of Thessaloniki (AUTH).

🔗 Registration is required:
https://www.athensdigitalhealth.eu/registration

EVOLVE2CARE Contributes to Open Science at the ManagiDiTH Winter School 2026

EVOLVE2CARE was featured during the ManagiDiTH Winter School and Innovation Bootcamp 2026, held in Finland from 26–30 January 2026, an intensive five-day programme combining innovation, entrepreneurship, and hands-on collaboration in the field of digital health.

The Winter School brought together students, researchers, enterprises, and academic partners to explore innovative health technologies through keynote sessions, teamwork, ideation, prototyping, and final concept presentations. Activities focused on bridging academic knowledge with real-world healthcare challenges, encouraging interdisciplinary collaboration and practical experimentation.

During the programme, Aristotle University of Thessaloniki (AUTH) presented EVOLVE2CARE as a concrete example of a European HealthTech project supporting Living Lab–based experimentation and Open Science practices. The presentation highlighted how EVOLVE2CARE contributes to transparent and responsible innovation in transitional care, while actively engaging with Open Science principles.

In particular, AUTH showcased the use of the RAISE platform for uploading and managing datasets generated through Living Lab activities, demonstrating how EVOLVE2CARE supports FAIR data practices and enables responsible data sharing across collaborative research environments.

Through its presence at the Winter School, EVOLVE2CARE strengthened its visibility within academic and innovation communities, while reinforcing its mission to support human-centred, data-aware HealthTech solutions that can be tested and refined in real-life settings.

EVOLVE2CARE Featured at the RAISE Final Event in Brussels

EVOLVE2CARE was featured during the RAISE Final Event – “Exploitable Results and their Impact”, held on 14 January 2026 in Brussels, as part of the midday session dedicated to the adoption of RAISE beyond project boundaries. The event brought together European research, Living Lab, and Open Science stakeholders to discuss how RAISE supports FAIR, harmonised, and transparent data use across third-party initiatives and collaborative ecosystems.

During the session, EVOLVE2CARE was presented by AUTH and ENoLL partners as a concrete example of a HealthTech project leveraging RAISE functionalities to align with Open Science and Open Data principles, particularly in the context of Living Lab activities. The presentation highlighted how EVOLVE2CARE exploits RAISE to support structured data management, facilitate collaboration between SMEs and Living Labs, and ensure FAIR handling of data generated through real-world experimentation.

The project’s contribution was positioned within a broader discussion involving Living Labs and European networks adopting RAISE to enable interoperable, trustworthy, and reusable research outputs. This visibility further reinforced EVOLVE2CARE’s role as an active adopter of EOSC-aligned tools and practices, strengthening its engagement with European Open Science infrastructures and sister EU initiatives.

From Testing to Adoption: What Makes HealthTech Solutions Ready for Real-World Deployment?

HealthTech innovation rarely fails because of a lack of ideas.
More often, it fails in the space between testing and adoption.

Many promising solutions perform well in pilot environments but struggle to scale, integrate into real healthcare settings, or gain long-term acceptance. The challenge is not proving that a technology works. The real challenge is proving that it is ready.

At EVOLVE2CARE, readiness is understood as a multi-dimensional journey, rather than just a final checkbox. Real-world deployment depends on whether solutions can respond to the practical, organisational, social, and regulatory realities of transitional care.

This blog builds on insights from Deliverable D1.2 – Stakeholder Needs Analysis and KPI Framework, which is publicly available and provides a deeper look into what makes HealthTech solutions ready for real-world deployment.

Why successful pilots don’t always lead to adoption

Testing a HealthTech solution in isolation can demonstrate technical feasibility, but real-world healthcare environments are far more complex.

Healthcare professionals operate under time pressure, fragmented systems, and strict accountability requirements. Hospitals must ensure that new solutions integrate smoothly into existing workflows without increasing workload or disrupting care delivery. Patients and caregivers need technologies that are understandable, usable, and supportive.

When these realities are not addressed early, innovations risk remaining “pilot-ready” but not system-ready.

Readiness starts with real-world relevance

A solution is ready for adoption when it demonstrates value where care actually happens.

Real-life experimentation helps innovators understand whether their solutions:

  • integrate into existing digital and organisational infrastructures
  • reduce administrative burden instead of adding complexity
  • support clinical decision-making in meaningful ways
  • improve patient experience, continuity of care, and outcomes

Living Labs play a critical role here by offering environments where innovations can be tested under realistic conditions, involving healthcare professionals, patients, caregivers, and organisations from the outset. This early exposure allows innovators to identify gaps, refine features, and adapt their solutions long before large-scale deployment.

Scaling requires more than technical performance

Moving beyond pilots requires attention to scale, sustainability, and long-term viability.

Healthcare organisations increasingly expect evidence that innovations are:

  • cost-effective and operationally efficient
  • adaptable to different care settings and regions
  • supported by training and knowledge transfer
  • aligned with broader health system goals

Regulatory preparedness as part of readiness

Regulatory compliance is often addressed late in the innovation process, creating delays and costly redesigns. However, readiness for deployment also means regulatory readiness.

Testing solutions in real-world settings helps innovators:

  • understand how regulations apply in practice
  • identify compliance challenges early
  • align development choices with safety, privacy, and legal requirements

Human-centred adoption

Readiness is ultimately about people.

Patients and caregivers have highlighted the importance of preserving human connection, clarity, and trust when digital solutions are introduced. Healthcare professionals have stressed the need for tools that support their expertise. Care organisations seek solutions that align with their operational realities.

Real-life experimentation allows these perspectives to shape innovation, ensuring that adoption is not forced, but earned through relevance and usability.

EVOLVE2CARE’s work on stakeholder needs and experimentation offers further insight into how readiness can be approached systematically across the HealthTech ecosystem. Readers interested in the methodological foundations behind this approach can further explore our public Deliverable D1.2 – Stakeholder Needs Analysis and KPI Framework.

Experimentation as a Trust-Building Tool in HealthTech

Why Real-Life Testing Matters for Patients, Providers, and Regulators

Trust is one of the most underestimated barriers in healthcare innovation.

HealthTech solutions promise better outcomes, smoother transitions, and more personalized care. Yet patients hesitate, healthcare professionals remain cautious, and regulators demand extensive evidence before approving deployment. The question is not whether innovation is needed, but whether it can be trusted.

At EVOLVE2CARE, we approach experimentation not as a technical checkpoint, but as a human, ethical, and social process. Real-life testing in Living Labs allows innovation to be shaped with people and not simply delivered to them.

Our approach is grounded in the work carried out within the project to better understand what different stakeholders truly need from HealthTech innovation in transitional care. These insights have been consolidated in Deliverable D1.2 – Stakeholder Needs Analysis and KPI Framework, which offers a deeper look into how experimentation can align innovation with real-world expectations across patients, healthcare providers, Living Labs, and regulators.

Why patients hesitate

For patients and caregivers, trust is deeply personal.

New digital health tools often raise concerns around data privacy, usability, and the fear that technology may replace, rather than support, human care. When innovations are introduced without sufficient explanation or involvement, uncertainty quickly turns into resistance.

Real-life experimentation helps address these concerns by actively involving patients and caregivers in the development process. Living Labs create safe, supportive environments where individuals can test solutions, provide feedback, and influence how technologies evolve. When patients see that their experiences, preferences, and limitations are taken seriously, trust begins to grow.

Why healthcare providers resist

Healthcare professionals operate in demanding environments, balancing patient care with administrative responsibilities and fragmented digital systems. New technologies are often perceived as adding complexity rather than relieving pressure.

Through real-life experimentation, healthcare providers can assess whether innovations genuinely integrate into existing workflows, reduce administrative burden, and support clinical decision-making. Testing solutions in realistic settings allows professionals to identify what works, what doesn’t, and what needs refinement before wider adoption.

Why regulators are cautious

Regulators play a critical role in safeguarding patient safety, data protection, and ethical standards. Their caution is not a barrier to innovation, but a necessary responsibility in a highly sensitive sector.

Living Lab experimentation offers regulators early insight into how HealthTech solutions function in real-world conditions. By observing technologies as they are tested with users, regulators can better understand emerging risks, ethical implications, and compliance challenges. Early engagement reduces uncertainty, helps avoid costly redesigns, and supports smoother pathways to approval.

Living Labs as trust enablers

Living Labs sit at the intersection of innovation, care delivery, and regulation.

Beyond providing physical spaces or technical infrastructure, Living Labs act as trusted intermediaries that facilitate transparent collaboration among patients, healthcare professionals, innovators, and policymakers. Living Labs ensure that ethical considerations, data protection, inclusivity, and societal context are embedded throughout the experimentation process and not only addressed as afterthoughts.

Trust is not built through promises or pilot demonstrations alone.
Trust is built through real-life evidence, transparency, and shared responsibility.

For readers interested in exploring the methodological foundations behind this trust-driven approach, Deliverable D1.2 – Stakeholder Needs Analysis and KPI Framework is publicly available and offers further insight into how real-life experimentation can support responsible HealthTech innovation in transitional care.


 

A conversation with Heikki Pitkänen on building a regulation-smart Europe

Europe’s innovators are full of ambition — but often struggle to navigate the maze of regulations that govern digital and health technologies. As new frameworks like the AI Act, Data Act, and European Health Data Space (EHDS) take shape, the need for clear, accessible, and practical regulatory literacy has never been greater.

We had a talk with Heikki Pitkänen, CEO and Founder of Lean Entries, a company that translates complex regulations into digital guidance tools for innovators, startups, and SMEs. Drawing from his decades of experience in medical device regulation, Heikki shares his insights on how Europe can turn compliance into a competitive advantage — and why simplifying complexity is the next big step for innovation.

Read the full interview below:

Question: Many innovators feel “drowned in regulatory complexity.” From your experience, what are the most common misconceptions or challenges among startups in digital health and MedTech?

I think the main challenge is that there are numerous regulations. It is a maze, and despite all the simplification from the European Commission and the European legislator’s perspective, the maze will remain. In my opinion, the more foundational issue is clarity—regulatory clarity, and as a result, regulatory literacy—which should be established at the earliest possible stage of innovation. What happens very typically is that innovator teams do not have the knowledge or prior experience in compliance with regulations. They often assume it can be addressed later, but in fact, regulations and related standards hold critical inputs that need to be considered from the start to avoid costly re-design. When establishing a company and writing a business plan, the regulatory strategy should be part of that package. This helps innovators understand what they face, make informed decisions, manage risks, and estimate costs.

Question: According to Mario Draghi’s 2024 report on the future of European competitiveness, over half of European SMEs see regulation as their No.1 barrier. How can we close this gap?

The reason, I think, is that many innovators don’t realize early on how critical it is to understand the basics. We’ve seen rare cases where founders have prior experience in highly regulated fields, like medical devices. These companies already have systems in place for the Medical Device Regulations (MDR or IVDR), so adding AI Act requirements—such as an AI life cycle or change management protocol—is straightforward. For them, compliance is practical, even though it consumes a substantial amount of resources and requires adapting to the evolving requirements for AI systems. But most early-stage teams lack this experience and miss the opportunity to make educated decisions on compliance. In my experience, this causes many failures and losses, not only in Europe but globally. This is also an opportunity for Europe to lead by improving compliance with its own and global regulations. Beyond top-down simplification, we need to recognize the foundational importance of bottom-up regulatory clarity. That is the most effective means of closing the gap.

Question: The EU is introducing several landmark regulations — AI Act, Data Act, European Health Data Space (EHDS) — all of which will shape the future of digital health. What do these mean for innovators in practice?

These regulations are designed with good intentions and offer clear benefits. For example, the EHDS aims to enable harmonised secondary use of health data across Europe, supporting faster development of AI-driven health solutions. However, practical challenges remain: How will the data-sharing work? Are hospitals and other data holders ready? What are the timelines for compliance? In practice, innovators face a steep learning curve with the increased maze. For early-stage innovators, the biggest hurdle is the overlap and volume of regulations. Recertification cycles add unnecessary burden while unannounced audits already keep manufacturers sharp with their processes. Greater trust and smarter monitoring could reduce this workload and the spending of resources.

Question: Lean Entries has developed e-tools that translate complex regulations like the Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), AI Act, Data Act, and European Health Data Space (EHDS) into step-by-step, no-code guidance. How do these tools work in practice, and how do they help innovators make compliance easier and faster from day one?

Our tools are delivered through partnerships with innovation hubs, universities, and clusters. These organizations provide the access free of charge to startups, SMEs, and public-sector teams, including translational researchers and even students. The platform applies a unique step-engine questionnaire that guides users through the myriad of regulatory requirements in a structured and personalized way. It builds on a fully referenced breakdown of regulations and related guidance documents, combined with examples, terminology, and guidance from those sources embedded directly in the interface, where innovators need it. The platform helps innovators navigate complex frameworks like the MDR or the AI Act, explore classification options, and find justification for whether a product qualifies as a medical device or not. 

This approach addresses the strong demand for regulatory clarity—critical for competitiveness and investor trust. Without regulatory literacy uncertainty remains and innovation slows. Today, Lean Entries offers the most nuanced and scalable tooling globally to establish regulatory clarity, covering multiple regulations and expanding to new ones like the Cyber Resilience Act and General Data Protection Regulation (GDPR). Furthermore, we are in the process of empowering the production of the tools with AI.

Question: How can we ensure that simplification doesn’t mean oversimplification — that innovators still internalize the “why” behind the rules?

Our experience shows that the Entries tools act as a wake-up call for innovators. They don’t solve all problems, but make them realize what they don’t know and where they need help. Unlike generic AI tools, like ChatGPT, which often give incomplete or unreferenced answers, the Entries platform provides structured guidance based on official sources and complete references. When innovators apply for support from a European Digital Innovation Hub (EDIH), university, or cluster, the Entries platform ensures they absorb essential knowledge. Compliance builds on that knowledge—setting up a regulatory strategy, Quality Management System (QMS) and implementing processes—but this first step is critical. Beyond guidance, Entries can be harnessed to collect valuable data points—currently over 800—from the five existing tools that could help universities, EDIHs, and the Commission understand what innovators are working on and where compliance hurdles exist. This way, we could serve innovators better and potentially match them directly through APIs to digital services and other service providers throughout their compliance journey. This enables the compression of value chains in innovation.

Heikki Pitkänen, CEO and Founder of Lean Entries

Question: Is Europe at risk of regulatory fragmentation — or can shared literacy frameworks, like those promoted through Lean Entries, help harmonize understanding across borders?

Regulatory fragmentation is a real challenge in Europe. While EU regulations aim for harmonization, many directives—such as NIS2 or the Machinery Directive—allow national deviations and interpretations. This means innovators often face 27 different variations layered on top of the core rules. Beyond safety, privacy and security regulations, there are additional administrative requirements like taxation, IP, and other compliance obligations, making cross-border expansion complex and costly. In my point of view, the European Commission should push for deeper harmonization, learning from best practices within EU Member States and aligning with global frameworks, including the U.S. and other regions. 

Question: How do you see AI sandboxes and EDIHs contributing to regulatory readiness? What should be done to make them more effective in supporting innovators?

AI regulatory sandboxes are a promising initiative, heavily supported by EU funding, to be launched by national competent authorities in August 2026. The assumed sandbox operators, such as EDIHs, already serve as key resources for innovators in the digital and AI space. They provide a strong foundation, but being still young, they need best practices, knowledge sharing and harmonisation of services across Europe. For EDIHs, we propose integrating regulatory literacy at the gateway of each hub. This means offering innovators clear, structured guidance on essential regulations as part of their onboarding process. Our platform Entries can act as a regulatory due diligence tool. Innovators entering an AI sandbox would first complete a basic compliance check through Entries, ensuring they know the most critical requirements, followed by local coaching, training or workshops to confirm their findings. This approach would also feed valuable data back to EDIHs, improving their support services. National competent authorities, Notified Bodies and service providers would experience more straightforward, value-adding transactions with innovators.We suggest starting with a pilot program, which could operate at minimal cost per EDIH to maintain and scale the system. This approach would not only strengthen regulatory readiness but also create feedback loops and analytics to improve support for innovators over time.

Question: You’ve called for a “shared literacy baseline.” What would that look like in practice? Who should lead it – the EU, national authorities, or innovation networks?

All stakeholders need to be involved—the EU, national authorities, and innovation networks. While much of what I’ve explained applies here, I believe the Entries tooling could be the key element to establish a regulatory literacy baseline. At the same time, I’d like to emphasise that training, coaching, and advice remain essential. These should continue through local regulatory experts in workshops where I recommend the innovators pitch their regulatory strategies and learn from peers. Existing elements, such as those offered by EDIHs, universities and incubators, should stay in place. The digital learning component simply creates the wake-up call, possibility to boost efficiency and provide a stable and harmonised learning curve. Activities carried out nationally or by EDIHs, Testing and Experimentation Facilities (TEFs) or AI factories would then become more effective. The European Commission should be strongly involved, endorsing or branding the initiative to show its support. Open-source APIs from Entries should be expected to make this most effective. Unfortunately, the topic of regulatory clarity, as foundational as it has become for European competitiveness, mostly dissolves under other priorities like funding and regulatory simplification. It’s time to make it a visible, actionable and measurable goal for the sake of our innovation!

Question: Can European projects like EVOLVE2CARE or organisations such as the European Network of Living Labs play a role in testing and scaling such literacy tools?

Absolutely. The health sector is an ideal environment for piloting regulatory literacy tools. Entries was originally developed for health tech, and our existing tools already cover key regulations such as MDR, IVDR, AI Act, Data Act, and EHDS. Future tools—like those for the Cyber Resilience Act and GDPR—will also impact healthcare systems. Projects like EVOLVE2CARE could provide the perfect environment to test and scale these tools in real-world settings.

Question: Looking ahead to 2030, what does a “regulation-smart Europe” look like to you?

By 2030, regulatory literacy should be a true baseline for innovators across Europe, supported by AI and data-driven tools. It will be assumed that innovators know what regulations mean for them. If they cannot show their regulatory data—such as classification, applicable regulations, and their compliance pathway—they cannot expect to receive funding or services from EDIHs and other parties. This will become a basic requirement, easily achievable through tools like Entries. By then, the digital and health tech sectors will have strong regulatory sandboxes. Universities and EDIHs will be able to perform due diligence on regulatory basics, ensuring innovators start from a shared understanding of compliance. From there, everyone remains free to compete and innovate, but with shared clarity on compliance. This common understanding will benefit innovators, investors, universities, and authorities alike. Five years is enough to establish this baseline for health tech and digital sectors, measure the results and continue expanding it to other industries.

Question: What message would you share with young innovators or startups who see regulation as a burden rather than a guide?

I think the baseline is that innovators need to understand that safety and security are the baselines for business when it comes to regulated sectors. If an innovator is developing a medical device, safety is the baseline for business. Many startups try to avoid regulatory work or costly clinical investigations. My advice is to integrate regulatory strategy into their business plans and budgets early—and use clinical investigations not only for compliance but also to collect valuable business data, engage early adopters, and strengthen market entry.

Start with what I call the eight early principles. The first four apply broadly:

  1. Qualification – Determine which regulations apply to the product.
  2. Classification – Understand the risk class and the workload ahead.
  3. List your standards – Recognise the best practices instead of re-inventing the wheel
  4. Regulatory Strategy – Make it part of the business plan.

The next four are health tech-specific but can be adjusted to other sectors:

  1. Literature reviews reveal existing clinical practices, competitors and benchmarks and are a natural first step into clinical evaluation and investigations.
  2. Whenever a team member speaks of risks, start writing them down, and collect a good bunch of more from the regulations and standards. Then let a risk management professional help you expand it into a full-blown risk management system.
  3. Study the feasibility of your product with good knowledge of the eventual safety and documentation requirements (i.e., design controls) in mind.
  4. Assess your most critical suppliers for their regulatory competence and include compliance in quality agreements. You should only work with suppliers that make your path to market easier, not harder.

Ignoring these principles creates a high risk of failure. Starting early saves months in the process and ensures your compliance aligns with business goals and market success.

Question: In such a complex regulatory landscape, do innovators need to develop multitasking skills to balance compliance, product development, and business growth?

Yes, absolutely. And innovators need to include early regulatory advice in their budget. If they cannot hire an experienced regulatory professional right away, consider combining a young expert with a consultant who can mentor them. This way, their team builds internal expertise over time to own their compliance, a key business enabler. This also means the leadership team should understand the basics of regulation, and their regulatory people should speak the language of business. Bridging that gap is essential. We’ve seen this challenge in MedTech for years, and now it’s hitting digital health and AI sectors, which face high-risk classifications and complex systems. The sooner innovators build this capability, the stronger their foundation for growth!

As Europe races to build a digital single market grounded in trust and transparency, voices like Heikki Pitkänen’s remind us that innovation and regulation aren’t opposites — they are partners in progress.

One-year EVOLVE2CARE project: Highlights from the 3rd Virtual Plenary Meeting

On November 4–5, 2025, the EVOLVE2CARE consortium gathered online for its 3rd Plenary Meeting, marking a key milestone: the conclusion of the project’s first year and the transition into its second and final phase.

This two-day online meeting served as a moment of reflection and strategic alignment. Partners reviewed progress across all areas of the project, celebrated achievements, and laid the groundwork for the next steps — with a clear shift in focus from building foundations to generating impact.

Highlights from the 1st year – Building strong foundations

Over the past year, EVOLVE2CARE has made significant strides in supporting innovation in Transitional Care:

  • Overall, the project has already achieved 9 out of 19 Key Performance Indicators (KPIs) — a strong signal of momentum and engagement. Work is actively underway to reach the remaining targets.
  • The Open Call for HealthTech innovators and Living Labs to collaborate and test digital solutions for Transitional Care scenarios attracted strong interest from EU’s ecosystems.
  • Two full training programs were delivered, featuring 12 webinars designed to empower both Living Labs and HealthTech innovators and researchers. These sessions helped build capacity, foster collaboration, and share practical knowledge across Europe.
  • The Accelup platform has continued to play a central role in the project as the matchmaking space between innovators and Living Labs. During the plenary meeting, partners shared feedback and discussed improvements to enhance its usability and ensure it remains a practical and intuitive place for collaboration.

Looking ahead – From results to impact

As EVOLVE2CARE enters its second year, the focus shifts toward disseminating outcomes, engaging with EU-level events, and contributing to policy dialogues. In fact, the project΄ key aims will revolve around:

  • Disseminating the results of the Open Call, with dedicated communication efforts to highlight the selected mini-projects and their expected impact; and
  • Organizing knowledge-sharing workshops to exchange best practices and insights with stakeholders.

Throughout the meeting, partners emphasized the importance of collaboration — not only within the consortium but also with external stakeholders, regulators, and decision-makers. The project’s second year will focus on turning lessons learned into actionable strategies, supporting the scalability and sustainability of innovations in Transitional Care. EVOLVE2CARE continues to connect people, platforms, and ideas — building a future where health innovation is inclusive, evidence-based, and ready to scale.